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Dengue 1–4 X X
Chikungunya X X
Yellow fever X
Zika X
Viruses Transmitted by Aedes aegypti and 
Aedes albopictus Mosquitoes
Weaver SC, Reisen WK. Antiviral Res 2010
4Aedes aegypti and Aedes albopictus Mosquitoes 
 Aedes (Stegomyia) subgenus
 Lay eggs in peridomestic water 
containers
 Live in and around households
 Peak feeding during daytime
 Aedes aegypti more efficient 
vector for humans
Aedes aegypti
Aedes albopictus
Schaffner F, Mathis A. Lancet Infect Dis 2014
5Approximate Distribution of Aedes aegypti and 
Aedes albopictus Mosquitoes
Kraemer M. Unpublished data (global maps) and ArboNET reports (US maps)
Aedes aegypti Aedes albopictus
6Epidemic (urban) cycleSylvatic (jungle) cycle
Aedes Mosquito-Borne Virus 
Transmission Cycles
MMWR 2010;59(RR-7)
7Sylvatic (jungle) cycle
Sylvatic (Jungle) Transmission Cycle
MMWR 2010;59(RR-7)
8Epidemic (urban) cycleSylvatic (jungle) cycle
Epidemic (Urban) Transmission Cycle
MMWR 2010;59(RR-7)
9Dengue Virus Types 1–4
 Four related viruses in genus Flavivirus
 Aedes aegypti is primary vector
 Aedes albopictus also transmits dengue viruses
 Humans are primary amplifying host
 Transmitted in epidemic (urban) cycle
 Sylvatic cycle no longer needed to maintain virus
Weaver SC, Reisen WK. Antiviral Res 2010
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Dengue Virus Types 1–4: 
Approximate Geographic Distribution
Bhatt S, et al. Nature 2013
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Dengue Virus Epidemiology
 Most important mosquito-borne viral disease
 30-fold increase in incidence over past 50 years
 25% of infected people develop clinical symptoms
 Ranges from mild febrile illness to life threatening disease
 Estimated 96 million disease cases in 2010
 67 million cases in Asia
 16 million cases in Africa 
 13 million cases in the Americas
Bhatt S, et al. Nature 2013
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Dengue Virus Disease and Outcomes
 Acute febrile illness often with
 Headache, retro-orbital pain, myalgia, and arthralgia
 Maculopapular rash
 Minor bleeding
 5–10% symptomatic patients develop severe disease
 Plasma leakage with shock or respiratory distress
 Severe hemorrhage
 Organ impairment
 Subsequent infection with different type of dengue 
virus increases risk for severe disease 
 Case fatality for severe dengue as high as 10%
 Proper case management reduces mortality to <1%
WHO 2009. http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf
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Chikungunya Virus
 Genus Alphavirus
 Aedes aegypti primary vector
 Aedes albopictus important in several recent outbreaks
 Humans primary amplifying host during outbreaks
 Sylvatic transmission in non-human primates in Africa
 Role of other animals in maintaining the virus not known
Thiberville SD, et al. Antiviral Res 2013
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Chikungunya Virus:
Approximate Geographic Distribution
Available at http://www.cdc.gov/chikungunya
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Chikungunya Virus:
Approximate Geographic Distribution
1950–2013
Available at http://www.cdc.gov/chikungunya
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Chikungunya Virus:
Approximate Geographic Distribution
2013–2015
Available at http://www.cdc.gov/chikungunya
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Chikungunya Virus Epidemiology
 Large outbreaks with high infection rates (≥30%)
 Majority (72%‒97%) of infected people symptomatic
 Over 1 million suspected cases reported in 2014
 Mostly in the Caribbean, and Central and South America
Staples JE, Fischer M. N Engl J Med 2014
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Chikungunya Virus Disease and Outcomes
 Primary clinical symptoms are fever and polyarthralgia
 Joint pain can be severe and debilitating
 Other common findings include headache, myalgia, 
arthritis, and maculopapular rash
 Acute symptoms typically resolve in 7‒10 days
 Some have persistent rheumatologic symptoms
 Case-fatality is low (<1%) and mostly in older adults
Thiberville SD, et al.  Antiviral Res 2013
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Yellow Fever Virus
 Genus Flavivirus
 Most human infections occur as a result 
of sylvatic (jungle) transmission
 Urban outbreaks occur periodically, 
mostly in West Africa
 Aedes aegypti is primary vector during 
urban outbreaks
MMWR 2010;59(RR-7)
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Yellow Fever Virus:
Approximate Geographic Distribution 
Jentes ES, et al. Lancet Infect Dis 2011
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Yellow Fever Virus Epidemiology
 30% of population infected during urban outbreaks
 10%–20% infected people develop clinical disease
 Estimated 200,000 cases annually worldwide
 85% of reported cases from sub-Saharan Africa
MMWR 2010;59(RR-7)
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Yellow Fever Virus Disease and Outcomes
 Acute febrile illness often presenting with headache, 
myalgia, vomiting, and lumbosacral pain 
 15% of symptomatic patients develop severe disease 
with jaundice, hemorrhage, or multiorgan failure
 Hyperbilirubinemia usually peaks toward the end of 
the first week of illness
 20%–50% case-fatality in patients with severe disease
MMWR 2010;59(RR-7)
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Zika Virus
 Genus Flavivirus
 Aedes aegypti believed to be primary vector
 Other Aedes (Stegomyia) mosquitoes have played important 
roles during recent Western Pacific outbreaks 
 Humans primary amplifying host during outbreaks
 Sylvatic transmission in non-human primates in Africa
 Role of other animals in maintaining the virus not known
Hayes EB. Emerg Infect Dis 2009
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Zika Virus:
Approximate Geographic Distribution 
Haddow AD, et al. PLoS NTD 2012
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Zika Virus Disease Epidemiology
 2007 outbreak in Yap resulted in an estimated 
900 cases (population 7,391)
 Estimated 73% of population infected in Yap
 18% of infected people develop clinical disease
 In 2014–2015, more than 30,000 suspected cases 
reported from French Polynesia and other 
Pacific islands
Duffy MR, et al. N Engl J Med 2009
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Zika Virus Disease and Outcomes
 Mild acute illness with a diffuse rash, arthralgia, 
and conjunctivitis
 Fevers are low grade and 25%–35% of patients 
may be afebrile
 Symptoms typically resolve over 3–7 days
 Few reports of possible Guillain-Barré syndrome 
or other severe disease manifestations
 No deaths reported
Hayes EB. Emerg Infect Dis 2009
Oehler E, et al. Euro surveillance 2014
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Diagnostic Testing for Dengue, Chikungunya, 
Yellow Fever and Zika Viruses 
 Viral RNA in blood within 3–7 days after onset
 IgM antibodies develop toward end of 1st week
 Neutralizing antibody testing to confirm results and distinguish 
infection by closely-related viruses
 ≥4-fold rise in virus-specific neutralizing antibodies 
on acute and convalescent specimens
 RT-PCR or immunohistochemical staining on 
autopsy tissues
RT-PCR: Reverse transcription-Polymerase chain reaction
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Treatment for Dengue, Chikungunya, 
Yellow Fever and Zika Viruses 
 No specific antiviral therapy; treatment is supportive
 Assess hydration and hemodynamic status
 Evaluate for other serious conditions and treat or 
manage appropriately
 Proper clinical management reduces mortality due 
to dengue 
 All suspected cases should be managed as if they have dengue 
until it has been ruled out
WHO 2009. http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf
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Vaccines for Dengue, Chikungunya, 
Yellow Fever and Zika Viruses
Virus Vaccine status
Dengue Phase 3 clinical trials
Chikungunya Phase 1–2 clinical trials
Yellow fever Licensed and available
Zika None
Villar L, et al. N Engl J Med 2015
Chang LJ, et al. Lancet 2014
Garske T, et al. PLoS Med 2014
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Prevention and Control of Dengue, 
Chikungunya, Yellow Fever and Zika Viruses 
 Community-level control efforts
 Mosquito habitat control
 Apply larvicide and adulticide
 Difficult to sustain at effective levels
 Personal protective measures
 Use air conditioning or window and door screens
 Use mosquito repellents on exposed skin
 Wear long-sleeved shirts and long pants
 Protect infected people from further mosquito 
exposure during first week of illness 
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Summary for Dengue, Chikungunya, 
Yellow Fever and Zika Viruses 
 Aedes aegypti most important vector during outbreaks
 Recent increased incidence and spread to new areas
 Overlapping geographic areas and clinical features
 No antiviral therapy but proper clinical management 
can reduce dengue mortality
 Yellow fever vaccine widely used; dengue and 
chikungunya vaccines in development
 Primary prevention is to reduce mosquito exposure 
but current vector-control options difficult to sustain
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The Status and Frontiers of Vector Control
Thomas W. Scott, PhD
Professor and Director
Vector-Borne Disease Laboratory
Department of Entomology and Nematology
University of California, Davis
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Environments That Favor More Mosquitoes 
 Aedes aegypti is highly domesticated 
 Stored water and discarded non-biodegradable items 
accumulate rain water, and create abundant mosquito 
development sites
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Environments that Favor More Mosquitoes 
and Transmission of Diseases 
 Rapid urban growth 
 Lack of adequate water supply 
 Lack of solid waste disposal 
 Substandard housing
 High human density support 
high Aedes aegypti densities 
with close biting contact 
to humans
 High virus transmission potential
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Ecology of Adult Aedes aegypti
 Adult females lay eggs on the sides of water holding containers
 In about 1 week, eggs hatch & larvae develop into pupae 
 Two days later adults emerge
 Adults rest inside houses
 Often in quiet, dark places like closets or clothes racks
 Adults do not move far 
 Often living their entire life in a single house or its neighbor 
 Seldom fly 100 meters from their initial resting site
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Population of Aedes aegypti
 Low population densities (e.g., few numbers 
of mosquitoes per house)
 Population tends to be focal and dynamic 
 Number of mosquitoes per house changes over time 
 Geographical distribution of 
infested houses varies 
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Vector Host Relationship of Aedes aegypti
 Only females feed on blood
 For egg development
 Prefer human source of blood
 “Day-biters” 
 Bite during the day when 
people are active 
 Average ~ 1 bite per day
 Biting more often leads to
 Increased fitness of mosquitoes 
 Live longer and lay more eggs
 Increased potential for virus transmission 
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Aedes aegypti Transmits 
Mosquito-Borne Diseases Efficiently 
 Biting a human host is required for virus transmission
 Low vertical virus transmission rate from females to their eggs
 Less than 1:1,500
 Biting patterns facilitate transmission
 Some people are bitten more than others, including visitors 
to homes
 Frequent human biting helps explain explosive epidemics
 Low entomologic transmission thresholds
 Epidemics can occur even when mosquitoes populations are low 
 They live, bite, and lay eggs close to humans
 They feed frequently and preferentially on human blood
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Vector Control to Stop the Spread of 
Mosquito-Borne Diseases 
 Vector control measures reduce 
 Adult mosquito population density
 Human biting rate
 Infectious mosquitoes; i.e., mosquito 
survival through the virus incubation period
 Target both larval and adult stages
 To be effective, vector control measures need to 
reduce mosquito populations
 Target levels at or just below level required for virus transmission
 Threshold density of the vector population
 They must also sustain those low levels 
 Defining transmission thresholds has been difficult
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Improving Measures of Entomological Risk 
Mosquito density index
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 Historical indices for immature 
mosquitoes do not predict 
human dengue infection risk
 Shift to pupae and adult 
mosquitoes indices requires 
understanding of complex 
interplay of many factors
 Susceptibility of human population; 
i.e., herd immunity
 Human biting rate
 Human host density
 Virus introduction
 Weather
Saturated 
transmission
Transmission 
not sustainable
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Existing Methods for Aedes aegypti
Control – Immature Stage 
Achee NL, et al. PLoS NTD 2015 
 Difficult to achieve and 
sustain epidemiologic impact 
with just larval control 
 Major categories include
 Containers 
 Cleaning (bleach/wash/dump)
 Manipulation (covers/treated covers)
 Treatment (insecticide/bio-control)
 Social campaigns
 Education and source reduction
 Environmental management
 Legislation
 Fines and penalties, if larva or 
pupae found
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Existing Methods for 
Aedes aegypti Control – Adult Stage 
Major categories include
(1) Space spraying (indoor vs outdoor)
(2) Indoor residual spraying
(3) Personal protection
Achee NL, et al. PLoS NTD 2015
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Interventions Currently Under Development 
Achee NL, et al. PLoS NTD 2015
RIDL: Release of Insects Carrying a Dominant Lethal
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Release of Insects Carrying a Dominant Lethal 
(RIDL) – Flightless Females
 Flightless females
 Males carrying a female-acting transgene mate with 
wild-type females
 Female offspring cannot fly
 Female offspring are unable to mate (cannot reproduce) 
or bite human hosts (cannot transmit virus)
 Heterozygote male offspring can mate and pass along transgene 
McGraw & O’Neill Nat Rev Micro 2013
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Release of Insects Carrying a Dominant Lethal 
(RIDL) – Kills Larvae
 Stage-specific killing
 Males carrying a transgene that causes late-acting lethality 
mate with wild-type females
 Offspring die as pupae 
 Reduces population density
 Successful safety testing and mosquito population 
reduction field trials
 Need to evaluate impact on human dengue outcomes
McGraw & O’Neill Nat Rev Micro 2013
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Naturally Occurring Bacteria – Wolbachia
Wolbachia is an endosymbiotic bacteria
 Commonly infects many insects
 Female Aedes aegypti experimentally infected with 
Wolbachia can pass the bacteria to their offspring
 Adult female Aedes aegypti infected with Wolbachia
have a 66%–75% reduced capacity to transmit dengue
http://en.wikipedia.org/wiki/Wolbachia
Wolbachia infected 
insect cell
Wolbachia
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Vector Control Using Wolbachia
McGraw & O’Neill Nat Rev Micro 2013
 Offspring from infected females are favored and spread 
Wolbachia through mosquito populations
 Field trials have successfully established Wolbachia in 
natural Aedes aegypti populations
 Field trials are testing the impact of releasing Wolbachia
infected Aedes aegypti on human dengue infection 
and disease
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CDC Autocidal Gravid Ovitrap (AGO) Trap
 Population reduction
 Removes egg laying and older, 
potentially dengue infected 
females
 Field trials in Puerto Rico 
detected sustained 
reduction in Aedes aegypti 
 Enhance effectiveness 
 By adding attractants
 Removing natural egg 
laying sites
Merits further evaluation
Barrera et al. J Med Ent 2014
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Working with Industrial Partners 
to Develop New Insecticides
 Three new active ingredients with 
novel modes of action available for 
vector control by 2020–2022
 Improvements in indoor residual 
spray and insecticide-treated 
materials
 Long lasting, repurposed insecticides for 
areas of high insecticide resistance and 
dual-treated materials
 Outdoor biting protection
 Supporting research on the prevention 
of pathogen transmission by mosquitoes 
that bite people outdoors
IVCC: Innovative Vector Control Consortium
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Combining Vector Control with Vaccines to 
Reduce Dengue Risk at Community Level 
 Vector control and vaccines should complement each 
other – resulting in a greater impact than either alone
 Vector control reduces each susceptible 
persons’ risk of being infected by 
reducing mosquito:
 Population density
 Human biting rate
 Survival
 Vaccination artificially elevates and 
sustains herd immunity
 Details for how these various strategies can best be 
combined need to be determined
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Summary and Implications
 Aedes aegypti is an efficient virus vector
 Epidemics can occur even at low mosquitoes densities
 Lack of appropriate infrastructure in cities allows 
for increasing Aedes aegypti populations with high 
potential for virus transmission
 Indoor residual insecticides have the greatest 
potential for reducing human infection and disease
 Emerging insecticide resistance is a growing concern 
for chemically-based interventions
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Steps Forward
 Need for epidemiologic assessment of interventions
 Insecticides
 Insecticide resistance monitoring and management
 New active ingredients and improving in indoor residual treatments
 Promising genetic-based strategies
 Release of Insects Carrying a Dominant Lethal (RIDL) 
 Wolbachia infected mosquitoes
 Scaling-up and maintaining coverage to prevent 
dengue remains a major challenge
 Integrated interventions will require carefully designed 
combinations of vector control with vaccines
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Prevention Strategies 
Aedes Mosquito-Borne Diseases 
Harold S. Margolis, MD 
Chief, Dengue Branch 
Division of Vector-Borne Diseases 
National Center for Emerging and Zoonotic Infectious Diseases 
Centers for Disease Control and Prevention 
San Juan, Puerto Rico 
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Dengue Infection and Dengue Disease 
 Dengue infection is largely asymptomatic for ~75% 
 For the rest, “dengue fever” or “dengue disease” 
 Acute febrile illness 
 Can present like many other diseases
 Typical course is 4-5 d fever, then resolves
 For ~10% with dengue disease, “severe dengue” 
develops
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Proper Case Management Critical to Survival
 Severe dengue (WHO, 2009)
 Plasma leakage which results in compensated or 
decompensated shock
 Includes a subset of individuals which develop
 Dengue hemorrhagic fever
 Dengue shock syndrome
 Life threatening, requires critical, supportive care
 Timely diagnosis improves prognosis
 If properly managed, case fatality rate less than 1%
 Early recognition of plasma-leakage, and compensated or  
decompensated shock based on presence of “warning signs” 
 Proper fluid management and resuscitation of plasma-leakage  
Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. New Edition. WHO, 2009 
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CDC Dengue Case Management 
E-Learning Course
Free CME Training:  cdc.gov/dengue/training/cme.html 
 CDC Dengue Case Management Educational tool 
 Designed for healthcare providers
 Includes case management steps recommended by WHO and 
incorporated in many dengue endemic countries   
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Better Diagnostics Leads to Better Outcomes
 Dengue is an acute febrile illness syndrome
 Similar presentation to chikungunya, leptospirosis, malaria, 
and other febrile illnesses  
 Clinical diagnosis often inconclusive
 Fever, rash, periorbital pain
 Accurate diagnosis needed
 Patient case management 
 Public health surveillance 
 Lab tests depend on timing in course of illness
 Cases often present as viremia wanes
 Both acute and convalescent needed for some serology
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Incubation
Period
Ave. 7 days
Sensitivity of Dengue Diagnostics 
Vary Over Course of Illness  
Peeling RW, et al. Nat Rev Microbiol 2010                         DENV: Dengue virus
Santiago GA, et al. PLoS NTD 2013 MAC: M antibody capture
CDC unpublished data PCR: Polymerase chain reaction
Dengue 
Febrile 
Phase
Ave. 5 days 
IgM anti-DENV 
MAC ELISA
Onset Fever
Post Febrile Phase
Viremia
PCR 
for
DENV
Critical 
Phase
1-2 
days
0 1    2    3    4    5    6    7    8    9    10  
Day Post Onset of Fever 
0   1   2   3   4   5    6
Exposure
90  
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Dengue Diagnostics Algorithm  
Day Post Onset of Fever 
Diagnostic Tests 
Reliability
RT-PCR IgM anti-DENV
0–3 + - ~90%
3–7 + + ~90%
>7 - + ~90%
Peeling RW, et al. Nat Rev Microbiol 2010                         DENV: Dengue virus
Santiago GA, et al. PLoS NTD 2013 RT-PCR: : Reverse transcription-Polymerase chain reaction
CDC unpublished data 
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Diagnostics 
Integrated 
Vector 
Control 
Vaccines 
A Framework for Dengue Prevention 
Secondary 
Prevention 
Case
Management 
Surveillance
and 
Education 
Adapted from: Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. New Edition. WHO, 2009  
Global Strategy for Dengue  Prevention and Control 2012-2020. WHO, 2012 
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 Repellents prevent all mosquito diseases, but…
 Must be reapplied
 Compliance low
 Several provide hours-long protection
 DEET, Picaridin (Icaridin), IR3535 
 Insecticide impregnated clothing (permethrin) 
 Must be periodically reapplied
 Impractical in endemic area  
 Do not provide community disease protection
Prevention Through Personal Protection
DEET: N,N-diethyl-m-toluamide
IR3535: 3-[N-Butyl-N-acetyl]-aminopropionic acid, ethyl ester
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Why A Dengue Vaccine?
 Mosquito control works, but expensive and difficult to 
sustain at effective levels
 Vaccines protect the individual and community
 Efficacious Flavivirus vaccines exist
 Yellow fever, Japanese encephalitis, tick-borne encephalitis   
 Technically feasible
 Challenge of dengue vaccine
 Must protect against all 4 viruses
 Implementation: 40% of world’s population at risk 
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Dengue Vaccine Candidates 
Producer
(developer) 
Approach
Sanofi Pasteur 
(Acambis) Live attenuated chimeric vaccine
Takeda 
(CDC, InViragen) Live attenuated chimeric vaccine
Butantan (NIAID)
Live attenuated , engineered mutations in 3 strains 
and chimeric in 2 
GSK (WRAIR) Cell culture derived inactivated vaccine
Merck 
(Hawaii Biotech) Subunits of DENV envelop protein 
GSK: GlaxoSmithKline
NIAID: National Institute of Allergy and Infectious Diseases
WRAIR: Walter Reed Army Institute of Research
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Dengue Vaccine Clinical Trial Phases 
Producer
Clinical Trial
Phase I Phase II Phase III
Sanofi Pasteur
Takeda 
Butantan 
GSK 
Merck 
GSK: GlaxoSmithKline
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Sanofi Dengue Vaccine Efficacy Trials  
Guidelines for the clinical evaluation of dengue vaccines in endemic areas PCR: Polymerase chain reaction
http://www.who.int/immunization/documents/WHO_IVB_08.12/en/
Capeding MR, et al. Lancet 2014
 Random, blinded, placebo-controlled (2:1) 
 Ages:  2-16 years (highest disease incidence) 
 3 doses:  given at 0, 6 &12 months 
 Vaccine – tetravalent, live, attenuated
 Placebo – normal saline vaccine diluent  
 End point: Symptomatic, confirmed dengue fever 
 Clinical acute febrile illness + PCR-detected viremia
 Follow-up:  25 months total (13 months after last dose) 
 Longer-term follow-up:  48 months
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DENV  
Types    
Phase IIB–Thailand
Ages 4–11, N= 4,002 
Phase III–Asia
Ages 2–14, N= 10,275 
Phase III–Latin 
America
Ages 9–16, N= 20,869 
Efficacy 95% CI Efficacy 95% CI Efficacy 95% CI 
All 
DENV’s   30.2
-13–57 56.5 44–66 60.8 52–68
DENV 1 55.6 22–84 50.0 25–67 50.3 29–65
DENV 2 9.2 -75–51 35.0 -9–61 42.3 14–61
DENV 3 75.3 -38–100 78.4 53–91 74.0 62–82
DENV 4 100 25–100 75.3 55–87 77.7 60–88
Results of Efficacy Trials 
Sanofi Vaccine (per protocol results) 
Sabchareon A, et al. Lancet  2012 DENV: Dengue virus 
Capeding MR, et al. Lancet 2014
Villar L, et al. NEJM 2015
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Sanofi Vaccine Trials Conclusions 
 Sanofi vaccine offers only partial protection
 DENV 2:  9%–42% efficacy 
 DENV 1:  about 50% efficacy
 Current data have not shown any vaccine 
safety issues 
 Long-term follow-up needed to evaluate immune 
cross reactivity from vaccination
 Natural immunity to one type of dengue can result in more 
severe course with subsequent infections with other types 
of dengue, whether this holds true for vaccine-derived 
immunity needs to be evaluated 
Sabchareon A, et al. Lancet  2012 DENV: Dengue virus 
Capeding MR, et al. Lancet 2014
Villar L, et al. NEJM 2015
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Dengue Summary 
 For 40% of the world’s population, dengue remains 
a threat
 Proper case management of severe dengue 
decreases mortality from ~ 10% to less than 1%
 Lab diagnostics depend on stage of illness
 Vector control and vaccine research holds promise
 Until a safe and effective vaccine is available, 
enhanced surveillance, rapid diagnosis, and 
personal protection are still the best methods for 
preventing dengue 
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Future Directions 
Model to evaluate the best way to implement vaccines
 Identification of target populations
 Develop new vector control options and ways to  
implement them at community level 
 Improve diagnostic tests 
 Needed for mosquito-borne viruses 
 Point-of-care, rapid diagnostic tests
 Increase universal dengue case management training
 Further our understanding of global burden of 
mosquito-borne diseases
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We Can Reduce the Global Burden of 
Mosquito-Borne Diseases 
 Timely diagnosis and proper case management can 
save lives
 Safe and effective vaccines are needed
 Surveillance needs to be enhanced 
 Vector control measures should be improved 
and sustained  
 Coordination of all of these components will increase 
the impact of these efforts 
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